Actively Recruiting
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
Led by Second Affiliated Hospital of Guangzhou Medical University · Updated on 2024-06-25
30
Participants Needed
1
Research Sites
678 weeks
Total Duration
On this page
Sponsors
S
Second Affiliated Hospital of Guangzhou Medical University
Lead Sponsor
F
Fapon Biotherapy Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The second generation of mesothelin targeted CAR-T cells that secret a fusion protein of IL21 and scfv against PD1 have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-T cells for immunotherapy of human cancer patients with Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the Mesothelin-CAR-T cell immunotherapy on human cancers will firstly be evaluated.
CONDITIONS
Official Title
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with advanced cancer that expresses Mesothelin protein
- Life expectancy greater than 12 weeks
- Adequate heart, lung, liver, kidney, and blood function
- Availability of autologous transduced T cells with at least 20% Mesothelin-CAR expression by flow cytometry and at least 20% killing activity against Mesothelin-positive targets in cytotoxicity assay
- Signed informed consent by patient or guardian with understanding and explanation provided
You will not qualify if you...
- Prior gene therapy treatment
- Severe viral infections such as HBV, HCV, or HIV
- Known HIV positivity
- Active infectious diseases caused by bacteria, viruses, fungi, or other pathogens
- Other severe illnesses deemed inappropriate by investigators
- Pregnant or breastfeeding women
- Systemic steroid treatment equal to or greater than 0.5 mg prednisone equivalent per kg per day
- Other conditions considered unsuitable by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510260
Actively Recruiting
Research Team
Z
Zhenfeng Zhang, MD, PhD
CONTACT
B
Bingjia He, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here